

Optimizing immunotherapy in locoregional and metastatic urothelial cancer

Dijk, N. van

Citation

Dijk, N. van. (2024, January 16). *Optimizing immunotherapy in locoregional and metastatic urothelial cancer*. Retrieved from https://hdl.handle.net/1887/3713954

Version: Publisher's Version

<u>Licence agreement concerning inclusion</u>

License: of doctoral thesis in the Institutional

Repository of the University of Leiden

Downloaded from: https://hdl.handle.net/1887/3713954

Note: To cite this publication please use the final published version (if applicable).

STELLINGEN

behorende bij het proefschrift getiteld

Optimizing immunotherapy in locoregional and metastatic urothelial cancer

- 1. Neo-adjuvant immunotherapy should become the clinical standard in urothelial cancer. this thesis
- 2. Preoperative combination immunotherapy is effective irrespective of pre-existing T-cell immunity in urothelial cancer. this thesis
- 3. PD-1/PD-L1 blockade alone is not sufficient as neo-adjuvant treatment in muscle-invasive bladder cancer. this thesis
- 4. The promising efficacy of neo-adjuvant immunotherapy paves the way for organ-sparing strategies in cancer. this thesis
- 5. Immunotherapy response prediction will always be limited by single-biopsy approaches.
- 6. All cancers are ultimately susceptible for immunotherapy treatment.
- 7. Always observe the tumor when results are surprising.
- 8. Immune checkpoint inhibition is less toxic than systemic chemotherapy.
- 9. The future is more interesting than the past, because the future is where I intend to live in.
- 10. I prefer being optimistic and wrong over being pessimistic and right.
- 11. Look up at the stars and not down at your feet.
- 12. You can either watch it happen or be a part of it.